Podcast

0.25 CME/CE Credit

Identifying and Testing for COPD in the Primary Care SettingPart 1: Lung Health Updates for Primary Care Providers: Conversations with NHLBI

“Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode on identifying and testing for COPD in primary care, we are joined by Dr. Antonello Punturieri, a Program Officer with NHLBI’s Division of Lung Diseases, and Dr. Byron Thomashow, Professor Emeritus at Columbia University Medical Center and Co-founder and Chief Medical Officer of the COPD Foundation. We’ll be discussing why primary care providers play such a crucial role in finding COPD cases among patients, the tools to help identify these cases, and the diagnostic criteria that points to starting appropriate treatments.

Begin

Already listened on another platform?

CME/CE Information

0.25 AMA PRA Category 1 Credits™

Release Date: 10/11/2022

Expiration Date: 10/11/2024

Topics

Learning Objectives

Review modifiable and non-modifiable risk factors for COPD
Discuss how and when to screen for COPD in primary care
Summarize the spirometric criteria for diagnosing COPD
Appreciate when a pulmonologist referral is recommended for patients with COPD
Discuss additional resources that clinicians can use for managing patients with COPD

Faculty

Antonello Punturieri, MD, PhD

Program Officer with National Heart, Lung, and Blood Institute, National Institutes of Health

Learn More

Byron Thomashow, MD

Professor of Medicine, Medical Director, Jo-Ann LeBuhn Center for Chest Disease, Columbia University Medical Center, New York, NY

Physician, Chairman, Board COPD Foundation, New York Presbyterian Hospital, New York, NY

Learn More

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Antonello Punturieri, MD: No financial relationships to disclose.

Byron Thomashow, MD: Consultant: RECKITT Health.

Pamela Kushner, MD: Stockholder: AstraZeneca.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and National Heart, Lung and Blood Institute’s Breath Better Network. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Education Partner

Learn More Breathe Better^®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.